$1.27 Billion is the total value of Vivo Capital, LLC's 42 reported holdings in Q1 2024. The portfolio turnover from Q4 2023 to Q1 2024 was 31.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Soleno Therapeutics Inc | $360,294,380 | +6.3% | 8,418,093 | 0.0% | 28.31% | +2.1% | ||
| GERN | Buy | Geron Corp | $89,843,464 | +76.4% | 27,225,292 | +12.8% | 7.06% | +69.3% |
| HRMY | Harmony Biosciences Holdings Inc | $87,517,774 | +4.0% | 2,606,247 | 0.0% | 6.88% | -0.2% | |
| SVA | New | Sinovac Biotech Ltd. | $76,346,000 | – | 11,800,000 | +100.0% | 6.00% | – |
| AVDL | Sell | Avadel Pharmaceuticals PLCadr | $67,088,752 | +16.0% | 3,972,099 | -3.0% | 5.27% | +11.3% |
| VRNA | Sell | Verona Pharma PLCsponsored ads | $58,087,748 | -31.2% | 3,610,177 | -15.1% | 4.56% | -34.0% |
| ALXO | ALX Oncology Holdings Inc | $47,053,535 | -25.1% | 4,220,048 | 0.0% | 3.70% | -28.1% | |
| DYN | Buy | Dyne Therapeutics Inc | $46,421,511 | +237.2% | 1,635,136 | +58.0% | 3.65% | +223.7% |
| TERN | Terns Pharmaceuticals Inc | $43,676,428 | +1.1% | 6,657,992 | 0.0% | 3.43% | -3.0% | |
| Sell | Astria Therapeutics Inc | $32,781,055 | +71.9% | 2,329,027 | -6.2% | 2.58% | +65.0% | |
| VRDN | Viridian Therapeutics Inc | $29,385,405 | -19.6% | 1,678,207 | 0.0% | 2.31% | -22.9% | |
| SLN | Buy | Silence Therapeutics PLCads | $23,877,806 | +169.4% | 1,105,454 | +116.7% | 1.88% | +158.4% |
| OLMA | Olema Pharmaceuticals Inc | $21,210,329 | -19.3% | 1,873,704 | 0.0% | 1.67% | -22.5% | |
| New | Adverum Biotechnologies, Inc. | $21,210,000 | – | 1,500,000 | +100.0% | 1.67% | – | |
| ALPN | Sell | Alpine Immune Sciences Inc | $20,794,175 | +33.2% | 520,505 | -36.5% | 1.63% | +27.8% |
| TARS | Sell | Tarsus Pharmaceuticals Inc | $20,557,743 | -43.1% | 565,550 | -68.3% | 1.62% | -45.4% |
| Verastem Inc | $18,153,840 | +45.0% | 1,538,461 | 0.0% | 1.43% | +39.2% | ||
| CRNX | Crinetics Pharmaceuticals Inc | $16,383,500 | +31.6% | 350,000 | 0.0% | 1.29% | +26.2% | |
| COGT | Cogent Biosciences Inc | $15,086,004 | +14.3% | 2,244,941 | 0.0% | 1.18% | +9.6% | |
| Sera Prognostics Inc | $15,019,004 | +52.2% | 1,650,440 | 0.0% | 1.18% | +46.0% | ||
| New | Regulus Therapeutics Inc | $14,400,000 | – | 5,000,000 | +100.0% | 1.13% | – | |
| Tourmaline Bio Inc. | $13,554,098 | -12.5% | 591,882 | 0.0% | 1.06% | -16.1% | ||
| CMPS | Compass Pathway PLCsponsored ads | $13,378,560 | -4.9% | 1,608,000 | 0.0% | 1.05% | -8.8% | |
| ORIC | Oric Pharmaceuticals Inc | $11,683,114 | +49.5% | 849,681 | 0.0% | 0.92% | +43.4% | |
| Engene Holdings Inc. | $11,504,050 | +83.6% | 678,705 | 0.0% | 0.90% | +76.2% | ||
| Genetron Holdings Ltdads | $10,899,925 | +9.4% | 2,708,056 | 0.0% | 0.86% | +5.0% | ||
| IO Biotech Inc | $10,680,049 | -8.0% | 6,173,439 | 0.0% | 0.84% | -11.7% | ||
| SVRA | Savara Inc | $10,399,849 | +6.0% | 2,088,323 | 0.0% | 0.82% | +1.6% | |
| ZLAB | Buy | Zai Lab Ltdadr | $8,509,792 | -24.4% | 531,198 | +29.0% | 0.67% | -27.4% |
| DCTH | Buy | Delcath Systems, Inc. | $7,950,378 | +123.5% | 1,666,746 | +94.9% | 0.62% | +114.8% |
| RZLT | Sell | Rezolute Inc | $7,134,145 | +121.7% | 2,797,704 | -13.7% | 0.56% | +112.5% |
| CMPX | Compass Therapeutics Inc | $7,040,926 | +26.9% | 3,556,023 | 0.0% | 0.55% | +21.8% | |
| Sell | Instil Bio Inc | $6,742,850 | +41.7% | 624,338 | -0.0% | 0.53% | +35.9% | |
| New | Q32 Bio Inc. | $6,305,959 | – | 370,068 | +100.0% | 0.50% | – | |
| BOLT | Bolt Therapeutics Inc | $4,929,807 | +25.0% | 3,521,291 | 0.0% | 0.39% | +19.8% | |
| Unicycive Therapeutics | $4,788,810 | +59.0% | 3,470,152 | 0.0% | 0.38% | +52.2% | ||
| ALLK | Allakos Inc | $3,764,880 | -53.8% | 2,988,000 | 0.0% | 0.30% | -55.7% | |
| ALGS | Aligos Therapeutics Inc | $3,476,089 | +47.6% | 3,547,030 | 0.0% | 0.27% | +41.5% | |
| DBVT | DBV Technologies SAsponsored ads | $2,029,218 | -21.4% | 2,708,875 | 0.0% | 0.16% | -24.6% | |
| CDXS | Codexis, Inc | $1,354,623 | +14.4% | 388,144 | 0.0% | 0.11% | +9.3% | |
| Aadi Bioscience Inc | $1,192,398 | +15.8% | 509,572 | 0.0% | 0.09% | +11.9% | ||
| New | Precision Biosciences Inc | $63,395 | – | 4,675 | +100.0% | 0.01% | – | |
| DTIL | Exit | Precision Biosciences Inc | $0 | – | -140,255 | -100.0% | -0.00% | – |
| FIXX | Exit | Homology Medicines, Inc. | $0 | – | -370,068 | -100.0% | -0.02% | – |
| ARWR | Exit | Arrowhead Pharmaceuticals Inc | $0 | – | -137,411 | -100.0% | -0.34% | – |
| IOVA | Exit | Iovance Biotherapeutics Inc | $0 | – | -655,057 | -100.0% | -0.44% | – |
| Exit | Rayzebio Inc | $0 | – | -110,581 | -100.0% | -0.56% | – | |
| PHVS | Exit | Pharvaris NV | $0 | – | -285,000 | -100.0% | -0.66% | – |
| KALV | Exit | KalVista Pharmaceuticals Inc. | $0 | – | -856,008 | -100.0% | -0.86% | – |
| Exit | Apogee Therapeutics Inc | $0 | – | -400,000 | -100.0% | -0.92% | – | |
| Exit | Icosavax, Inc. | $0 | – | -1,704,568 | -100.0% | -2.20% | – | |
| GRCL | Exit | Gracell Biotechnologies Incsponsored ads | $0 | – | -9,546,485 | -100.0% | -7.85% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-04-22
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 32 | Q2 2024 | 8.0% |
| ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
| Verona Pharma PLC ADR | 27 | Q2 2024 | 7.6% |
| KALVISTA PHARMACEUTICALS INC | 26 | Q4 2023 | 3.9% |
| ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
| Zai Lab Ltd ADR | 25 | Q2 2024 | 1.8% |
| AMYRIS INC | 23 | Q3 2023 | 8.8% |
| EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
| Arrowhead Pharmaceuticals Inc | 22 | Q4 2023 | 6.9% |
| HOMOLOGY MEDICINES INC | 22 | Q4 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-26 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-04-22 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-08 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.